IP Library Granted Patent US 11,186,829
Granted Patent B2
US 11,186,829 · App. 16/423,811 · Granted Nov 30, 2021

Isolated mammalian somatic cells containing modified RNA encoding OCT4, SOX2, and KLF4

Inventors: Derrick Rossi (Roslindale, MA); Luigi Warren (Boston, MA)
Assignee: Children's Medical Center Corporation
C12N5/0696C07K14/435C12N15/11C12N15/111C12N2310/14C12N2320/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,186,829
App. No.
16/423,811
Granted
Nov 30, 2021
Kind
B2
Abstract

Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.

Claims (11)

1. An isolated, mammalian somatic cell comprising exogenously introduced synthetic, modified RNA encoding Oct4, Sox2, and Klf4, wherein each cytosine of the synthetic modified RNA is replaced with 5-methylcytosine and each uracil of the synthetic modified RNA is replaced with pseudouracil.

2. The cell of claim 1 , wherein the cell is a human cell.

3. The cell of claim 1 , wherein the cell is not a human cell.

4. The cell of claim 1 , wherein the synthetic, modified RNA further comprises a 5′ cap.

5. The cell of claim 4 , wherein the 5′ cap is a 5′ cap analog.

6. The cell of claim 5 , wherein the 5′ cap analog is a 5′ diguanosine cap.

7. The cell of claim 1 , wherein the synthetic, modified RNA does not comprise a 5′ triphosphate.

8. The cell of claim 1 , wherein the synthetic, modified RNA further comprises a poly(A) tail, a Kozak sequence, a 3′ untranslated region, a 5′ untranslated region, or any combination thereof.

9. The cell of claim 8 , wherein the poly(A) tail, the Kozak sequence, the 3′ untranslated region, the 5′ untranslated region, or the any combination thereof comprises one or more modified nucleosides.

10. The cell of claim 1 , wherein the synthetic, modified RNA is treated with an alkaline phosphatase.

11. The cell of claim 1 , wherein the cell or its immediate precursor cell(s) is derived from a somatic cell, partially reprogrammed somatic cell, a pluripotent cell, a multipotent cell, a differentiated cell, or an embryonic cell.

Assignments (4)
MERGER Recorded Nov 21, 2022
From: IMMUNE DISEASE INSTITUTE, INC
To: THE CHILDREN'S HOSPITAL CORPORATION
Reel/Frame 061842/0006 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2022
From: THE CHILDREN'S HOSPITAL CORPORATION
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 061842/0010 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2022
From: WARREN, LUIGI
To: IMMUNE DISEASE INSTITUTE, INC
Reel/Frame 061842/0017 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2022
From: ROSSI, DERRICK
To: IMMUNE DISEASE INSTITUTE, INC.
Reel/Frame 061842/0023 →
Continuity (6)
Division 15692518 · Aug 31, 2017
Continuation 14311545 · Jun 23, 2014
Continuation 13088009 · Apr 15, 2011
Provisional Application 61325003 · Apr 16, 2010
Provisional Application 61387220 · Sep 28, 2010
Related Publication 20190382729A1 · Dec 19, 2019